| Patent(s) and the Corresponding Patented Drug(s) |
Top |
| World Intellectual Property Organization (WIPO) |
| Patent ID |
WO2017136451 |
| Title |
Hdac1/2 Inhibitors for The Treatment of Neurodegenerative and/or Cognitive Disorders. |
| Abstract |
Provided herein are compounds, pharmaceutical compositions comprising such compounds, and methods of using such compounds to treat or prevent diseases or disorders associated with HDAC activity, particularly diseases or disorders that involve activity of HDAC1 and/or HDAC2. |
| Applicant(s) |
Regenacy Pharmaceuticals, Llc |
| Representative Drug(s) |
D0C9NX |
Drug Info
|
IC50 = 43 nM |
[1] |
| Patent ID |
WO2017040564 |
| Title |
Hdac Inhibitors and Therapeutic Methods Using The Same. |
| Abstract |
Histone deacetylases inhibitors (HDACIs) and compositions containing the same are disclosed. Methods of treating diseases and conditions wherein inhibition of HDAC provides a benefit, like a cancer, a neurodegenerative disorder, a peripheral neuropathy, a neurological disease, traumatic brain injury, stroke, hypertension, malaria, an autoimmune disease, autism, autism spectrum disorders, and inflammation, also are disclosed. |
| Applicant(s) |
The Board of Trustes of the University of Illinois |
| Representative Drug(s) |
D0LN1T |
Drug Info
|
IC50 = 22800 nM |
[1] |
| Patent ID |
WO2017039726 |
| Title |
Novel Hdac Inhibitors and Methods of Treatment Using The Same. |
| Abstract |
Disclosed herein are novel HDAC inhibitors. The HDAC inhibitors may be used in methods of treating cancer. The HDAC inhibitors may be used in methods of treating a neurological disorder. |
| Applicant(s) |
Uwm Research Foundation, Inc |
| Representative Drug(s) |
D0JB4S |
Drug Info
|
IC50 = 839.3 nM |
[1] |
| Patent ID |
WO2016090230 |
| Title |
Pyrimidine Hydroxy Amide Compounds for Treating Peripheral Neuropathy. |
| Abstract |
The invention relates to HDAC inhibitors for the treatment of peripheral neuropathy in a subject in need thereof. Also provided herein are methods for treating peripheral neuropathy in a subject in need thereof comprising administering to the subject a therapeutically effective amount of an HDAC inhibitor. |
| Applicant(s) |
Acetylon Pharmaceuticals, Inc |
| Representative Drug(s) |
D0Q1QY |
Drug Info
|
IC50 = 158 nM |
[1] |
| Patent ID |
WO2016018795 |
| Title |
Histone Deacetylase Inhibitors. |
| Abstract |
Provided herein are brain penetrant histone deacetylase (HDAC) inhibitors useful for treating diseases or disorders associated with HDAC. An exemplary HDAC inhibitor provided herein exhibits a brain-to-plama ratio of 20: 1. Pharmaceutical compositions comprising HDAC inhibitors and methods for treating diseases associated with HDAC are also provided. |
| Applicant(s) |
The General Hospital Corporation |
| Representative Drug(s) |
D0DI9S |
Drug Info
|
IC50 = 0.6 nM |
[1] |
| Patent ID |
WO2015175813 |
| Title |
Heterocyclic Hydroxamic Acids As Protein Deacetylase Inhibitors and Dual Protein Deacetylase-Protein Kinase Inhibitors and Methods of Use Thereof. |
| Abstract |
The present invention relates to novel hydroxamic acids which are specific histone deacetylase (HDAC) inhibitors and/or TTK/Mpsl kinase inhibitors, including pharmaceutically acceptable salts thereof, which are useful for modulating HDAC and/or TTK/Mpsl kinase activity, pharmaceutical compositions comprising these compounds, and processes for their preparation. |
| Applicant(s) |
The Regents of the University of Colorado, A Body Corporate |
| Representative Drug(s) |
D0BP8I |
Drug Info
|
IC50 = 140 nM |
[1] |
| Patent ID |
WO2015054474 |
| Title |
Pyrimidine Hydroxy Amide Compounds As Histone Deacetylase Inhibitors. |
| Abstract |
Provided herein are compounds, pharmaceutical compositions comprising such compounds, and methods of using such compounds to treat or prevent diseases or disorders associated with HDAC activity, particularly diseases or disorders that involve activity of HDACl, HDAC2, and/or HDAC6. Also provided herein are methods for inhibiting migration of a neuroblastoma cell, inducing maturation of a neuroblastoma cell, and altering cell cycle progression of a neuroblastoma cell comprising administering to the cell a therapeutically effective amount of a HDACl, HDAC2, and/or HDAC6 selective inhibitor or a pharmaceutically acceptable salt thereof. |
| Applicant(s) |
Acetylon Pharmaceuticals, Inc |
| Representative Drug(s) |
D0EH2K |
Drug Info
|
IC50 = 546 nM |
[1] |
| Patent ID |
WO2014178606 |
| Title |
Novel Compounds for Selective Histone Deacetylase Inhibitors, and Pharmaceutical Composition Comprising The Same. |
| Abstract |
The present invention relates to novel urea derivatives and, more particularly, to novel urea derivatives with histone deacetylase (HDAC) inhibitory activity, isomers thereof, pharmaceutically acceptable salts thereof, their use for the preparation of a medicaments comprising the same, a pharmaceutical composition comprising the same, a treatment method using the composition, and a method for preparing novel urea derivatives. The novel urea derivatives as selective histone deacetylase (HDAC) inhibitors are effective for the treatment of histone deacetylase-mediated diseases such as malignant tumors, inflammatory diseases, rheumatoid arthritis, neurodegeneration, etc. |
| Applicant(s) |
Chong Kun Dang Pharmaceutical Corp |
| Representative Drug(s) |
D0LP1K |
Drug Info
|
IC50 = 10300 nM |
[1] |
| Patent ID |
WO2014152444 |
| Title |
Histone Deacetylase Inhibitors. |
| Abstract |
Proivded herein are compounds and methods for inhibiting histone deacetylase ("HDAC") enzymes (e.g., HDACl, HDAC2, and HDAC3). |
| Applicant(s) |
Biomarin Pharmaceutical Inc |
| Representative Drug(s) |
D0OU0J |
Drug Info
|
IC50 < 1000 nM |
[1] |
| Patent ID |
WO2014143666 |
| Title |
Hdac Inhibitors. |
| Abstract |
Disclosed herein are compounds of formula (I), and methods of inhibiting histone deacetylase ("HDAC") enzymes (e.g., HDAC1, HDAC2, and HDAC3) using compounds of formula (I). |
| Applicant(s) |
Biomarin Pharmaceutical Inc |
| Patent ID |
WO2014122222 |
| Title |
Hydroxamate Derivatives Bearing Amide-Lactams As Potent Hdac Inhibitors and Their Uses As Medicaments. |
| Abstract |
The present invention relates to novel amide compounds of Formula (I), and their use as anti-tumoral and pro-apoptotic agents. The invention includes the use of such compounds in medicine, in relation to cancer disease as well as other diseases where an inhibition of HDAC is responsive, and the pharmaceutical composition containing such compounds. |
| Applicant(s) |
Sigma-Tau Industrie Farmaceutiche Riunite Spa |
| Representative Drug(s) |
D0N2DK |
Drug Info
|
IC50 < 150 nM |
[1] |
| Patent ID |
WO2013041480 |
| Title |
New Thio Derivatives Bearing Lactams As Potent Hdac Inhibitors and Their Uses As Medicaments. |
| Abstract |
The present invention relates to novel amide compounds of Formula (I), and their use as anti-tumoral and pro-apoptotic agents. The invention includes the use of such compounds in medicine, in relation to cancer disease as well as other diseases where an inhibition of HDAC is responsive, and the pharmaceutical composition containing such compounds. |
| Applicant(s) |
Sigma-Tau Industrie Farmaceutiche Riunite Spa |
| Representative Drug(s) |
D07WAT |
Drug Info
|
IC50 = 100 to 500 nM |
[1] |
| Patent ID |
WO2013005049 |
| Title |
N- (2 -Aminophenyl) Benzamide Derivatives As Histone Deacetylase Inhibitors. |
| Abstract |
This invention relates to the discovery of novel compounds, or pharmaceutically acceptable salts thereof, which possess HDAC inhibitory activity. In particular, the compounds of the invention demonstrate selectivity towards Class I HDAC enzymes, and are accordingly expected to be useful for their anti-proliferative activity and in methods of treatment of the human or animal body, for example in preventing or inhibiting tumour growth and metastasis in cancers. The invention also relates to processes for the manufacture of the compounds defined herein, or pharmaceutically acceptable salts thereof, to pharmaceutical compositions containing them and to their use in the manufacture of medicaments for use in the production of an anti-proliferative effect in a warm-blooded animal such as man. |
| Applicant(s) |
Cancer Research Technology Limited |
| Representative Drug(s) |
D0CH8Q |
Drug Info
|
IC50 = 28.7 nM |
[1] |
| United States Patent and Trademark Office (USPTO) |
| Patent ID |
US20170044185 |
| Title |
Preparation of Histone Deacetylase (Hdac) Inhibitors and Methods for Use Thereof. |
| Representative Drug(s) |
D0RA0D |
Drug Info
|
IC50 = 1310 nM |
[1] |
